YARDLEY, Pa., June 2, 2021 /PRNewswire/ — Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy ...
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback